A very short, efficient and inexpensive synthesis of the prodrug form of SC-54701A. A platelet aggregation inhibitor
A short and efficient synthesis of the prodrug form of SC-54701A has been achieved from (trimethylsilyl)acetylene in 6 steps with an overall yield of 19%.
Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists
Our initial orally active fibrinogen receptor antagonist benzamidinopentanoyl (BAP) series which was discovered through truncation of our iv antiplatelet agent (SC-52012) demonstrated modest oral activity in canine studies (ethyl [5-(4-amidinophenyl)penta